WWOX activation by toosendanin suppresses hepatocellular carcinoma metastasis through JAK2/Stat3 and Wnt/beta-catenin signaling

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Loss of WW-domain containing oxidoreductase (WWOX) has been proven to be associated with malignant metastasis in patients with HCC. In this study, by using a non-biased CRISPR knockout genetic screen targeting 19,050 human genes, we found that toosendanin (TSN) is a novel druggable WWOX candidate agonist for metastatic HCC patients. We also found that TSN exhibited significant anti-proliferative and anti-metastatic effects on HCC cells in a WWOX-dependent manner. Overexpression and knockdown of WWOX in vitro and in vivo confirmed that the suppression of HCC by TSN involved WWOX. TSN regulated Stat3, DVL2, and GSK3 beta by transforming their interactions with WWOX as demonstrated by a Co-IP assay. TSN accelerated the degradation of beta-catenin by promoting the function of APC, AXIN1, CK1, and GSK3 beta complex. Nuclear translocation of p-Stat3 Y705 and beta-catenin was impeded by the TSN-induced blockade of JAK2/Stat3 and Wnt/beta-catenin signaling, accompanied by the inhibition of MMPs and C-MYC.

Automated summary

This study reveals that toosendanin (TSN) may be a novel druggable WWOX agonist for metastatic hepatocellular carcinoma (HCC) patients, showing significant anti-proliferative and anti-metastatic effects on HCC cells in a WWOX-dependent manner. TSN regulates multiple signaling pathways by altering their interactions with WWOX, providing potential therapeutic implications for HCC treatment.